Saltar al contenido
Merck
  • Iron status in patients with pyruvate kinase deficiency: neonatal hyperferritinaemia associated with a novel frameshift deletion in the PKLR gene (p.Arg518fs), and low hepcidin to ferritin ratios.

Iron status in patients with pyruvate kinase deficiency: neonatal hyperferritinaemia associated with a novel frameshift deletion in the PKLR gene (p.Arg518fs), and low hepcidin to ferritin ratios.

British journal of haematology (2014-02-19)
Renata Mojzikova, Pavla Koralkova, Dusan Holub, Zuzana Zidova, Dagmar Pospisilova, Jaroslav Cermak, Zuzana Striezencova Laluhova, Karel Indrak, Martina Sukova, Martina Partschova, Jana Kucerova, Monika Horvathova, Vladimir Divoky
RESUMEN

Pyruvate kinase (PK) deficiency is an iron-loading anaemia characterized by chronic haemolysis, ineffective erythropoiesis and a requirement for blood transfusion in most cases. We studied 11 patients from 10 unrelated families and found nine different disease-causing PKLR mutations. Two of these mutations - the point mutation c.878A>T (p.Asp293Val) and the frameshift deletion c.1553delG (p.(Arg518Leufs*12)) - have not been previously described in the literature. This frameshift deletion was associated with an unusually severe phenotype involving neonatal hyperferritinaemia that is not typical of PK deficiency. No disease-causing mutations in genes associated with haemochromatosis could be found. Inappropriately low levels of hepcidin with respect to iron loading were detected in all PK-deficient patients with increased ferritin, confirming the predominant effect of accelerated erythropoiesis on hepcidin production. Although the levels of a putative hepcidin suppressor, growth differentiation factor-15, were increased in PK-deficient patients, no negative correlation with hepcidin was found. This result indicates the existence of another as-yet unidentified erythroid regulator of hepcidin synthesis in PK deficiency.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Pyruvate Kinase from rabbit muscle, Type III, lyophilized powder, 350-600 units/mg protein
Sigma-Aldrich
Ferritin from equine spleen, Type I, saline solution
Sigma-Aldrich
Pyruvate Kinase from rabbit muscle, Type II, ammonium sulfate suspension, 350-600 units/mg protein
Sigma-Aldrich
Pyruvate Kinase from rabbit muscle, Type VII, buffered aqueous glycerol solution, 350-600 units/mg protein
Sigma-Aldrich
Ferritin from human liver, Type IV, 10 μg/mL
Sigma-Aldrich
Pyruvate Kinase from Bacillus stearothermophilus, Type VIII, lyophilized powder, 100-300 units/mg protein
Sigma-Aldrich
Ferritin from human spleen, Type V, 10 μg/mL in 0.15 M NaCl, 10 mM Tris, pH 8.0, containing 0.1% sodium azide